HealthCare, Technology Briefing: Market Movers for the Week - Technologies-Scan Corp, GNC, Galena Biopharma, Immunomedics, Amarin
CORAL SPRINGS, Florida, August 26, 2013 /PRNewswire/ --
FinancialNewsMedia.com issues news updates for today's HealthCare Leaders in the news that are positioned to trade higher from current levels: Technologies-Scan Corp (OTCQB: TENP), GNC Holdings Inc (NYSE: GNC), Galena Biopharma (NASDAQ: GALE), Immunomedics, Inc. (NASDAQ: IMMU) and Amarin Corporation plc (NASDAQ: AMRN).
Technologies-Scan Corp (OTCQB: TENP) Headline: Technologies-Scan Corp announces upcoming USA launch for its Proteina21 weight loss product line. Technologies-Scan Corp (OTCQB: TENP) is pleased to announce the upcoming USA launch of its Proteina21 product line scheduled for November 1 2013 thus entering the $66 Billion Dollar USA weight loss market. The company has ordered thru Social Geek Media, it's licensor of the Proteina21 license for the USA, the necessary product inventory for its initial USA launch. Proteina21 is a product line of food supplements and readymade meals high in protein and low in carbohydrates designed to help people lose weight. The Proteina21 product line will consist of several different weight loss products. The products are shipped overnight and are available thru internet sales on their website http://www.proteina21.com.
Get an in-depth look at Technologies-Scan by viewing this informative presentation from Online Digital Magazine: http://www.creativemedianetwork.info/technoscan/index.html
To read the entire press release, please go to http://www.fnmprofiles.com/profiles-tenp.php
A study of analyst recommendations at the major brokerages indicate that GNC Holdings Inc (NYSE: GNC) is the #14 broker analyst pick among those stocks screened by The Online Investor (http://www.theonlineinvestor.com/) for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period. In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the list of stocks with strong buyback activity was ranked according to those averages. GNC Holdings, Inc. operates as a specialty retailer of health and wellness products. It operates through three segments: Retail, Franchise, and Manufacturing/Wholesale.
Galena Biopharma (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, recently announced the European Patent Office notified the Company of an intention to grant a Pharmaceutical Use Patent for NeuVax(TM) (nelipepimut-S). The patent covers the use of NeuVax as a vaccine for the prevention of relapse in breast cancer patients with an immunochemistry (IHC) rating of 1+ or 2+ for HER2/neu protein expression and a fluorescence in situ hybridization (FISH) rating of less than 2.0 for HER2/neu gene expression.
Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, reported financial results for the fourth quarter and fiscal year ended June 30, 2013. The Company also highlighted recent key developments and planned activities for its clinical pipeline. To read the Fourth Quarter Fiscal 2013 Results go to http://finance.yahoo.com/news/immunomedics-announces-fiscal-2013-results-200000249.html
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. Vascepa[(R)] (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA and is available by prescription. AMRN closed up 9cents per share on Friday (August 23, 2013) on over 3.9Million shares traded.
Microsoft Corp. (NASDAQ: MSFT) is expected remain in the spotlight on Monday as investors assess whether to extend the Ballmer bounce -- the best one-day gain in four years on the news CEO Steve Ballmer planned to retire. Read the full article at http://www.marketwatch.com/story/microsoft-is-mondays-stock-to-watch-2013-08-24?siteid=yhoof2.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup. Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PRESS to 545454. (SMS alerts are free, however data rates may apply, check your wireless plan for details.)
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group LLC
More by this Source
Cannabis Sector Advances Cautiously - Company's CEO Discusses 1st Quarter Financials
Apr 14, 2014, 09:05 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.